A Study of CS5001 in Patients With Advanced Solid Tumors and Lymphomas
Phase 1
480
about 5.8 years
18+
3 sites in NY, TX
What this study is about
This trial is testing the safety and preliminary effectiveness of a new drug called CS5001 in people with advanced lymphoma or solid tumors. The treatment will be given as a single agent or in combination with other medications.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Receive Rituximab
- 2.Take CS5001
- 3.Take Cyclophosphamide
- +3 more
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
cyclophosphamide (Alkylating chemotherapy; crosslinks DNA strands), doxorubicin (Anthracycline chemotherapy; intercalates DNA and inhibits topoisomerase II), gemcitabine, lenalidomide (Immunomodulatory drug; affects immune system and cancer cells (exact mechanism unclear)), oxaliplatin, prednisone, rituximab (Monoclonal antibody; targets CD20 on B-cells to destroy them), vincristine
infusion, injection (Injection), oral (Oral Capsule), oral
Primary: Incident and severity of adverse events, Maximum Tolerated Dose (MTD) of CS5001 if any (for dose escalation part), Objective Response Rate (ORR) (for dose expansion)
Oncology